The potential for metabolism-related drug-drug interactions by new chemical entities is assessed by monitoring the impact of these compounds on cytochrome P450 (CYP) activity using well-characterized CYP substrates. The conventional gold standard approach for in vitro evaluation of CYP inhibitory potential uses pooled human liver microsomes (HLM) in conjunction with prototypical drug substrates, often quantified by LC-MS/MS. However, fluorescent CYP inhibition assays, which use recombinantly expressed CYPs and fluorogenic probe substrates, have been employed in early drug discovery to provide low-cost, high-throughput assessment of new chemical entities. Despite its greatly enhanced throughput, this approach has been met with mixed success in predicting the data obtained with the conventional gold standard approach (HLM+LC-MS). The authors find that the predictivity of fluorogenic assays for the major CYP isoforms 3A4 and 2D6 may depend on the quality of the test compounds. Although the structurally more optimized marketed drugs yielded acceptable correlations between the fluorogenic and HLM+LC-MS/MS assays for CYPs 3A4, 2D6, and 2C9 (r 2 = 0.5-0.7; p < 0.005), preoptimization, early discovery compounds yielded poorer correlations (r 2 ≤ 0.2) for 2 of these major isoforms, CYPs 3A4 and 2D6. Potential reasons for the observed differences are discussed. (Journal of Biomolecular Screening 2008;343-353) 
INTRODUCTION
C OADMINISTRATION OF DRUGS, a common clinical practice, often produces adverse drug-drug interactions (DDIs) as a result of increased plasma concentration of one of the drugs. This event is most often a consequence of one drug directly inhibiting the metabolism of the other. 1, 2 Most new chemical entities (NCEs) are metabolized predominantly in the liver by cytochrome P450 (CYP) enzymes, particularly CYP isoforms 3A4, 2D6, and 2C9. 3 The exceptionally broad substrate specificity for metabolism by these enzymes underlies the basis for competition that leads to most clinically relevant DDIs.
According to the current guidance of the US Food and Drug Administration (FDA), when drug coadministration increases the in vivo area under the curve or maximal plasma concentration (Cmax) of one of the coadministered drugs by more than 2-fold, this constitutes a clinically relevant DDI. 4, 5 Such DDIs are estimated to be responsible for about a half million adverse drug reactions occurring every year in the United States alone. 6 Numerous drugs have been subsequently recalled from clinical use as a result of potentially fatal DDIs. 3 It has become a common strategy for pharmaceutical companies to attempt to minimize late-stage attrition, potential market restraints, and serious clinical complications by assessing undesirable drug exposure risks early in drug discovery. 1 To minimize DDI risks in drug development, an accepted approach is to probe metabolism-related DDIs in vitro by monitoring the impact of the NCE on CYP metabolic activity using well-characterized CYP substrates. For early risk assessment, a few basic assumptions permit IC 50 values, obtained from in vitro assays, to be used as reasonable predictors of K i for an inhibitor. The use of in vitro CYP inhibition data for the prediction of in vivo DDIs has been demonstrated. 1 In recent years, 2 main approaches have been available for obtaining in vitro CYP inhibition data.
The recognized gold standard approach to generating CYP inhibition data uses human liver microsome (HLM) preparations and prototypical drug substrates as selective probes of individual CYP isoforms. 5 This approach has been regarded for its retention of multiple metabolic pathways, characteristic of in vivo metabolism, and use of compatible in vivo probe substrates. An additional advantage is that this approach is endorsed by the FDA for the evaluation of new drugs. However, this approach has historically been labor intensive, requiring long analytical run times, and, consequently, not easily amenable to the high-throughput demands of early drug discovery. In recent years, advances in LC-MS/MS have allowed increased throughput, offering great promise for the implementation of high-quality, high-throughput approaches at the earliest phases of compound assessment. 7 As an alternative to the gold standard approach, fluorescent CYP inhibition assays, using recombinantly expressed CYPs (rCYPs) with fluorogenic probe substrates, introduced within the past decade, have routinely been employed with mixed success. [8] [9] [10] This approach has been heavily favored for use in early discovery because of its simple readout, low cost, rapid turnaround, and high throughput. However, interference by test compounds with intrinsic fluorescence and/or fluorescence quenching must be cautiously monitored as confounders of fluorogenic data. This was generally registered as an acceptable trade-off for the advantages outlined above.
The introduction of the fluorogenic approach allowed establishment of a cascaded DDI risk assessment paradigm in drug discovery. The fluorogenic approach was presumed to flag most of the NCEs with a high potential DDI risk, whereas the gold standard HLM+LC-MS/MS assays were allocated to confirm risk before compounds entered development. Accumulating evidence, though, highlights noteworthy discrepancies in IC 50 predictions using recombinant CYPs with fluorogenic probes versus the traditional approach. One recent study of the CYP inhibition potential of anti-infective drugs found that results obtained in the fluorescence assay correlated well with the conventional, well-established, gold standard methods using HLMs. 11 Other groups, however, have revealed a troubling lack of correlation between values obtained in the fluorogenic versus traditional approaches. 12, 13 Failure of the fluorogenic CYP inhibition assays to correlate well with the gold standard methods is consistent with our observations at Novartis. 14 Specifically, IC 50 values generated during drug discovery using the fluorogenic assays have not been predictive of later risk assessment using the HLM+LC-MS/MS assays. The current study was initiated to systematically compare the inhibitory potencies of marketed drugs and Novartis discovery compounds in the fluorogenic and traditional approaches to determine the optimal profiling strategy for Novartis' drug discovery program. We found that, especially for Novartis' proprietary drug discovery set, the fluorogenic assays were poorly predictive of CYP inhibition data by the gold standard method. The observations from this study raise concerns about the role of the fluorogenic assays, especially for early in vitro DDI risk assessment.
MATERIALS AND METHODS

Materials
β-Nicotinamide adenine dinucleotide phosphate reduced tetrasodium salt was obtained from Calbiochem (San Diego, CA). Standard CYP probe substrates (midazolam, diclofenac), CYP control inhibitors (ketoconazole, quinidine, sulfaphenazole, fluvoxamine) and LC-MS/MS internal standards (alprenolol, sulfadimethoxine) were purchased from Sigma Aldrich (St. Louis, MO). The 2D6 probe substrate bufuralol was purchased from Ultrafine Chemicals (Manchester, UK). The fluorogenic reagents dibenzylfluorescein (DBF), 7-methoxy-4-trifluoromethylcoumarin (MFC), and 3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-methylcoumarin (AMMC) were obtained from BD Gentest Corp. (Woburn, MA). Novartis discovery compounds were obtained from the Novartis compound library. All test compounds were provided as 10 mM DMSO stock solutions and were serially diluted in DMSO for inhibition assessment. The same test article stock solutions were used for the comparisons of CYP inhibition assays.
Pooled (27 donor, mixed gender) human liver microsomes were purchased from BD Gentest Corp., as were the CYP 3A4+OR+ b 5 , CYP 2D6*1+OR, CYP 2C9*1+OR+ b 5 , and control Supersomes™. The marketed compounds evaluated in these assays were obtained either directly from Sigma Aldrich or supplied, as 10-mM DMSO solutions, from the Novartis compound library, with the exception of fluconazole, which was obtained from ICN Biomedicals, Inc. (Costa Mesa, CA); ritonavir, from Toronto Research Chemicals, Inc. (Ontario, Canada); terbinafine, from APIN Chemicals Ltd (Oxon, UK); and omeprazole and simvastatin, from USP (Rockville, MD).
CYP inhibition by HLM+ +LC/MS-MS method
Prior to initiation of the CYP inhibition reactions, both reaction times and microsomal protein concentrations were verified to be within the limits of kinetics linearity (not shown). All probe substrate concentrations selected for these determinations were less than or approximately equal to the apparent reaction K m .
Incubations were conducted in a 96-well plate format at 37 °C with shaking. Reactions were initiated by adding an equal volume (50 μL) of a 2-mM NADPH solution to a 2× suspension of enzyme, substrate, and inhibitor. The final incubation (100 μL total volume) contained HLM protein in 100 mM potassium phosphate buffer (pH 7.4), 5 mM MgCl 2, 1 mM NADPH, and test article tested at 50, 16.7, 5.6, 1.9, 0.6, 0.2, 0.1, and 0 μM. The probe reactions for CYP 3A4 were conducted with 2.0 μM midazolam and 0.05 mg/mL HLM protein for 10 min. The CYP 2D6 probe reaction was conducted with 7.0 μM bufuralol and 0.1 mg/mL HLM protein for 15 min. The CYP 2C9 probe reaction was conducted with 10 μM diclofenac and 0.2 mg/mL HLM protein for 15 min. Reactions were terminated with the addition of a quench solution (200 μL) of acetonitrile containing 1.5 μM alprenolol (for 4′-hydroxydiclofenac analysis) or sulfadimethoxine (for all other analytes) as internal standards for LC-MS/MS. Positive control reactions included ketoconazole (10 μM) for CYP 3A4, quinidine (0.5 μM) for CYP 2D6, or sulfaphenazole (10 μM) for CYP 2C9. Negative control reactions included 0.1% DMSO for all isoforms. Reaction supernatants, clarified by 10 min of centrifugation at 2100 relative centrifugal force (RCF; 4 °C), were analyzed by LC/MS-MS for relative quantification of metabolite (1′-hydroxy-midazolam, 4′hydroxy-diclofenac, or 1′-hydroxy-bufuralol) generated from the probe substrate.
LC/MS-MS
Quantitative analysis of probe substrate metabolites in quenched reaction supernatant was performed using an Agilent 1100 series liquid chromatograph (Agilent Technologies, Palo Alto, CA) equipped with a Micromass Quattro Premier (triple quadrupole) mass spectrometer (Waters, Milford, MA). Chromatographic separation was achieved using a Phenomenex Synergi Polar-RP (50 × 2 mm, 4 μm) column (Phenomenex, Torrance, CA) preceded by a Synergi Polar-RP 2 × 4 mm precolumn. The column temperature was 25 °C, and the flow rate was 1 mL/min. The mobile phase consisted of 2 solvents: (A) 10 mM ammonium formate in water and (B) 0.1% formic acid in acetonitrile. The total analysis time was 2 min, with a step gradient achieving 5% to 95% of B in 1.7 min. The mass spectrometer was operated in multiple-reactionmonitoring mode. Integration of reaction product and internal standard peak areas was performed using Quanlynx software (version 4.0).
CYP inhibition by rCYP+ +fluorescence method
Fluorogenic CYP inhibition studies were conducted at 37 °C in 384-well, flat-bottom, black polystyrene plates. Supersome™ mixtures containing CYP protein, insect control Supersomes™, substrate, and potassium phosphate buffer (pH 7.4) were prepared with the following final concentrations: CYP 3A4, 8 pmol/mL 3A4+OR+b 5 Supersomes™ + 0.8 μM DBF in 175 mM buffer; CYP 2D6, 12 pmol/mL 2D6*1+OR Supersomes™ + 1.2 μM AMMC in 25 mM buffer; and CYP 2C9, 12 pmol/mL CYP 2C9*1+OR+ b 5 + 60 μM MFC in 25 mM buffer. Insect control Supersomes™ were included in all reactions at a final concentration of 0.06 mg/mL. Reaction times were verified to be within the limits of kinetics linearity (not shown). All probe substrate concentrations selected for these determinations were approximately equal to the K m . Test compounds in DMSO (5 μL) were combined with 20 μL of the enzyme-substrate solution, and reactions were initiated by the addition of 25 μL 0.5 mM NADPH. Incubation times for CYPs 3A, 2D6, and 2C9 were 20, 30, and 45 min, respectively. At final reaction times, fluorescence was determined (without quenching) using the following excitation/emission wavelengths: 3A4 (485/535 nm), 2D6 (390/465 nm), and 2C9 (409/535 nm). Fluorescence signals were used to estimate IC 50 s as described in the Data Analysis section. A separate control incubation for fluorescent interference contained test compound (50 μM) and insect control microsomes (at a concentration equal to the inhibition incubations). A compound was excluded from the data set if the fluorescent signal from the control incubation was >30% of the dynamic window for the reaction, as evidence of fluorescence interference.
Data analysis
The analyte:internal standard peak area ratios (PARs; HLM+ LC/MS-MS method) or the fluorescence signals (rCYP+ fluorogenic method) within a dilution series were normalized to 0% to 100% inhibition, using the range defined by the positive and negative control inhibitors for each isoform/substrate as described in the HLM+LC-MS/MS Method section. The equation used for normalization is as follows:
where %I is the percentage inhibition at a particular concentration after normalization, I is the PAR or fluorescence signal at that test concentration, I PC is the PAR or fluorescence signal observed at the highest concentration of the PC standard, and I NC is the average signal for all points in an NC series (N = 8 per isoform, with each concentration in singlet). The normalized data were fitted with a 4-parameter logistic fit to determine the IC 50 . Upper and lower limits for the IC 50 measurements were set at 50 μM and 0.07 μM, respectively. IC 50 values ≤0.07 μM or ≥50 μM were designated as qualified values. For visualization of results, all data were included, and upper and lower qualified data were represented using the respective values of 51 μM and 0.05 μM. Assay correlations (r 2 ) were evaluated from best-fit linear regression analysis using only the nonqualified log IC 50 values with Microsoft™ XLFit (version 4.0). General DDI risk binning is based on the criteria of IC 50 <1 μM (high risk), 1 to 10 μM (medium risk), or >10 μM (low risk).
RESULTS
Evaluation of inhibitory potential between assays
In the initial evaluation of the assays, a panel of marketed drugs was assessed for inhibitory potential using fluorogenic sub-strates+rCYP isoforms and compared with the inhibition in the HLM+LC-MS/MS assays. The key differences between the 2 assay approaches are summarized in Table 1 . For the marketed drug set, the inhibition trends were clear for all 3 isoforms and the extent of the linear relationship between the assays was acceptable for early discovery risk assessment (r 2 = 0.51-0.69, p < 0.005; N = 15-18 marketed drugs per isoform; Table 2 ; Fig. 1 ). Although marketed drug sets evaluated in the CYP 3A4 and 2C9 assays did not appear to correlate as well as those compounds evaluated in the CYP 2D6 assay (lower r 2 ), these data alone would still be sufficient to support the use of the fluorogenic assays for rapid, early risk binning based on IC 50 values, with ∼75% of all compounds maintaining the same general risk bin regardless of the assay approach used. This observation was consistent with overall correlations reported by others using marketed compounds 15 yet is not reflective of our historical success rates with proprietary compounds in using these assays to predict gold standard CYP inhibition. 14 To address this disconnect, a subsequent assessment of the assays was performed using Novartis' discovery compounds. A panel of new chemical entities from the Novartis compound library was analyzed, side by side, in the 2 assay formats. The predictivity of the fluorogenic assays became clearly more problematic for the discovery test set ( Table 3 ; Fig. 2) . The utility of the fluorescence-based assays in predicting LC-MS/MS-based IC 50 s was quite poor for the HLM/midazolam versus 3A4/DBF (r 2 = 0.21, p < 0.001; N = 46) and HLM/bufuralol versus 2D6/AMMC assays (r 2 < 0.005, p < 0.85; N = 10). The predictivity observed for proprietary compounds in the HLM/diclofenac versus 2C9/MFC assays appeared comparable to that of the marketed drug panel ( Fig. 2C ; r 2 = 0.68, p < 0.006; N = 10). The correlation coefficients for the different assay approaches were compared with the Fisher Z-transform 16 to evaluate whether the differences in correlation strength between marketed and discovery test sets were significant. For CYP 2D6, the correlations between the test sets were found to be significantly different (p < 0.006). The CYP 3A4 correlations, however, compared with the lower confidence for statistical significance (p < 0.09). The CYP 2C9 assays were not determined to be statistically different (p < 0.57).
The geometric mean fold errors (GMFEs) between the IC 50 s generated in the 2 assays was further used to evaluate possible differences in test set performance and offer a basis for comparing data scatter between test sets. The GMFE was calculated using equation 2:
where fold error equals fluorescence IC 50 /MS IC 50 if fluorescence IC 50 >MS IC 50 or MS IC 50 /fluorescence IC 50 if MS IC 50 > fluorescence IC 50 . The GMFEs for the CYP 3A4 and 2C9 test sets were not different: 4.0 for marketed compounds versus 3.8 for discovery compounds in the CYP 3A4 assay and 3.0 for marketed compounds versus 2.7 for discovery compounds in the CYP 2C9 assay. The GMFEs for the CYP 2D6 test sets, however, were considerably different, 2.5 for marketed compounds versus 12.5 for discovery compounds, further supporting a difference in performance of these test sets between the 2D6 assays.
DISCUSSION
A general relationship between IC 50 and K i , where [S] is the concentration of substrate used in the in vitro IC 50 determination, can be summarized as follows:
When IC 50 values for a competitive or uncompetitive enzyme inhibitor are determined under appropriate conditions (i.e., linearity of kinetics) with relevant probe substrates at a concentration approximating K m , the apparent IC 50 approximately equals 2*K i . IC 50 is closer to K i if the type of inhibition is noncompetitive. 5 Therefore, appropriately determined IC 50 values should fulfill the criteria of K i ≤ IC 50 ≤ 2*K i . It is worth commenting that the type of inhibition usually cannot be discerned under the basic assay protocol employed for most IC 50 determinations. Reversible competitive inhibition is generally assumed for all NCEs at the earliest level of drug safety risk assessment. This approximation of K i (within ∼2-fold) provides, in turn, a useful basis for estimation of potential in vivo drug interactions. 4 Overall, the predictivity of the fluorogenic assays, as reflected using the marketed drugs, supports a reasonable basis for general risk assessment (binning) during drug discovery screening against these major CYP isoforms. This was in contrast to the cumulative observation at Novartis that discovery profiling data (using rCYPs+fluorogenic probes) has traditionally correlated poorly with LC-MS/MS CYP inhibition characterized for the same compounds using HLM+prototypical drug substrates. 14 We previously reported an internal analysis, compiled from 79 randomly selected discovery compounds tested in both CYP 3A4 assay formats, that revealed a very weak assay correlation (HLM+midazolam versus rCYP 3A4+DBF; r 2 = 0.3). The side-by-side analyses presented here support this general observation, which is consistent, as well, with the correlation predicted in a similar study by Nomeir and others. 17 These data argue that the fluorogenic results obtained during early lead optimization are insufficient for assessment of DDIs for discovery compounds and may establish a foundation for erroneous compound prioritization and structure redesign. Because the accuracy of the IC 50 evaluation is essential for estimation of potential in vivo DDIs and prioritization of discovery compounds, the nuances of a particular assay system should be carefully evaluated. This finding is supported by other published comparisons of the performance of the fluorogenic-and LC-MS/MS-based assays. 12 There are several key differences between the fluorogenic and LC-MS/MS approaches that may account for compound performance differences between the 2 assays ( Table 1) . The dependence of isoform inhibition on the selected substrate should not be ignored. In the classical view of enzymology, the K i of a given inhibitor toward an enzyme is a constant of the inhibitor, independent of substrate used, and the inhibitor should have the same K i value for all substrates that are catalyzed by the same enzyme. However, this assumption is challenged when substrates and inhibitors may not be expected to compete for access to a single site.
Of particular relevance to drug discovery, studies have shown that the kinetics of CYP 3A4, implicated in the metabolism of more than half of marketed drugs, is especially sensitive to the choice of probe substrate. 8, 13 Kenworthy and others 13 previously used rCYP 3A4 to compare the performance of ∼10 CYP 3A4 substrates for IC 50 determination. For a single panel of inhibitors, the authors observed correlation coefficients ranging from 0.21 to 0.85, with the fluorogenic probe substrate having the poorest correlation. 13 There is growing evidence that inhibition data for many CYP 3A4 substrates are inconsistent with classic Michaelis-Menten kinetics. 18 Reports of positive cooperativity, substrate inhibition, and the proposed existence of at least 2 substrate binding sites of CYP 3A4, with the potential to be simultaneously occupied, confound any major assumptions for this enzyme. [18] [19] [20] [21] [22] This consideration underlies the current industry standard to evaluate the inhibitory potential of CYP 3A4 with at least 2 probe substrates. 5 Although substrate/isoform interaction may account for the general lack of correlation between the 2 assay formats, it would not explain the potential difference between marketed and discovery drug test sets. It is reasonable to suspect, rather, that a critical contribution from the liver microsomes used in the gold standard assay is involved. Unlike the fluorogenic approach, which includes only a single CYP isoform in each reaction well, the HLMs in the LC-MS/MS approach support retention of an array of complementary drug-metabolizing liver CYPs, more closely approximating the in vivo scenario. The traditional probe substrates used in these LC-MS/MS approaches have demonstrated good selectivity for isolated CYP isoforms at the concentrations used. The test compounds used as inhibitors, however, especially at the earliest stages of discovery, are presumably not selective. From this perspective, some reaction systems may rely more heavily on the fate of the inhibitors tested rather than the probe substrates employed.
Compounds that are rapidly metabolized by human liver microsomes during the course of IC 50 measurements may be subject to underestimation of inhibitor potential in the microsomal system, relative to measurements made simply with rCYPs, because of lower effective concentrations of parent drug in the assay. Alternatively, overestimation of inhibition might be expected if inhibiting metabolites are formed. In theory, discovery compounds, having not yet been optimized for metabolic stability, might suffer from generally higher CYP-mediated metabolism and may therefore be more sensitive to the substitution of HLM with rCYP than the marketed drugs. This may be especially relevant for CYP 2D6, which is present in relatively low abundance (∼2% of total CYP protein) in human liver microsomes. 23 Other effectors of microsomal DDIs, such as ancillary proteins, should also be considered in the context of test compound metabolic fate. Drug-metabolizing CYPs are almost exclusively localized in the endoplasmic reticulum, where the mono-oxygenase system consists of cytochrome P450 and accessory proteins, such as NPR and cytochrome b 5 , that supply the P450 with reducing equivalents. It has been demonstrated that accessory protein interactions may contribute to apparent DDIs arising in liver microsomes, especially for test compounds competing for metabolism by multiple CYPs. 24, 25 Undoubtedly, discovery drugs suffer not only from suboptimal metabolic properties but also from suboptimal physicochemical properties. Compound solubility, a well-known source of variability for in vitro profiling, was not available for much of the marketed and discovery test sets used in our comparisons. However, most of the test set (marketed and discovery) were shown to have interassay reproducibility in at least 1 of the CYP inhibition approaches (data not shown). Compounds found to be irreproducible within either assay format were omitted from the test set. Still, it cannot be ruled out that a physicochemical difference between the test sets might underlie the differences observed. The overall comparison of formula weight (FW), cLogP, and polar surface area (PSA) between the marketed and discovery test sets indicated that the FW and PSA distributions were significantly different between the data sets (p < 0.05; Table  4 ). Although the distribution range was similar for FW and PSA, discovery compounds tended to appear larger and more highly substituted (FW >400 = 81% for discovery compounds v. 43% for marketed drugs; PSA >50 = 96% for discovery compounds v. 57% for marketed drugs). It is possible that these properties may affect the behaviors of the compounds differently between assays. Table 3 .
CONCLUSIONS
Although the ease of use and availability of the fluorogenic assay systems have certainly helped to catapult an awareness of the need for early CYP inhibition assessments, it is becoming apparent that these assays may have inherent deficiencies that undermine their application for compound prioritization and structure redesign activities during discovery. The differing correlations between test sets for the fluorogenic and LC-MS/MS assays raise concerns regarding the utility of the fluorogenic assays, especially for early in vitro DDI risk assessment, and signal a warning that merits additional investigation, giving attention to larger data sets. In light of the complex setting for evaluation of metabolic DDIs, it is prudent to employ high-quality assays in the discovery process to avoid exhausting resources on poorly characterized compounds or underestimating the drug-to-market potential based on faulty assumptions. Considerations such as analytical sample pooling, IC 50 versus single concentration determinations, and tiered isoform assessment should be weighed in the design of a manageable drug discovery effort. 26 
